| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Gene Transfer Increases the Sensitivity of Etoposide-resistant Human Breast Cancer Cells1
Departments of Cancer Biology [Z. Z., Y. K., T. A., E. S. K.] and Pediatrics [C. H., E. S. K.] and Division of Medicine [L. A. Z.], The University of Texas M. D. Anderson Cancer Center, and Department of Cell Biology, Baylor College of Medicine [K. K.], Houston, Texas 77030
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
(topo II) gene expression. Etoposide-resistant MDA-VP human breast cancer cells express lower amounts of enzymatically active and drug-sensitive topo II than do MDA parent cells, suggesting that the low level of topo II is the mechanism of resistance. To determine whether transfer of a normal topo II gene into MDA-VP cells can increase topo II gene expression, topo II protein production, and cell sensitivity to etoposide, a recombinant adenovirus, Ad-hTopoII, containing the human topo II gene, was constructed. The shuttle vector pAvCvSv-hTopII was constructed and cotransfected with the pBHG10 packaging vector into 293 cells. Infectious recombinant adenovirus plaques were isolated and purified. Presence of the topo II gene was confirmed by PCR and restriction enzyme digestion. After infection with Ad-hTopoII, topo II mRNA expression in MDA-VP cells increased 7.4-fold, topo II protein production increased 5.9-fold, and sensitivity to etoposide was enhanced 4.5-fold compared with control transfected cells. Infection of normal human embryonic lung cells and human fibroblast cells with Ad-hTopoII did not enhance the expression of topo II or sensitivity to etoposide. Viral uptake was comparable in the MDA-VP and normal cell lines. These data suggest that topo II gene transfer using an adenoviral vector can selectively increase etoposide sensitivity in drug-resistant tumor cells and may enhance the therapeutic index of etoposide. |
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
3
(1)
. The topo II nuclear enzyme is essential to the survival of eukaryotic cells (2, 3, 4, 5)
. It is involved in DNA replication, chromosome segregation, and other essential cellular processes. Topo II is also a target for a variety of clinically important antineoplastic drugs, including etoposide (VP-16) and Adriamycin. Topo II-targeted drugs act as topo II poisons by stabilizing the enzyme-DNA cleavable complex. This stabilization initiates a biochemical cascade, leading to cell death. The resistance to topo II-targeted drugs involves quantitative and/or qualitative alterations in topo II gene expression. Mutations in the gene are associated with the production of a mutated topo II protein that is less able to cleave DNA in the presence of antineoplastic agents (6)
. Low cellular levels of topo II lead to reduced formation of drug-stabilized topo II-DNA cleavable complexes, which quantitatively correlate with cell death (7)
. The cytotoxicity of topo II-targeted drugs tends to increase as cellular topo II content increases. MDA-VP human breast cancer cells, which are resistant to VP-16, express lower amounts of topo II than do MDA parent cells (8)
. Therefore, elevation of the topo II level could theoretically result in increased drug sensitivity.
Our previous studies have shown that transient transfection with a vector containing either the Drosophila or human topo II gene into drug-resistant tumor cells enhanced their drug sensitivity (8
, 9)
. Transient transfection of MDA-VP cells with a glucocorticoid-inducible vector carrying the human topo II gene increased human topo II mRNA and protein levels, increased cleavable complex formation, and enhanced sensitivity to the topo II-reactive drugs VP-16, doxorubicin, and amsacrine (8)
. Although this vector was suitable for in vitro testing, highly efficient gene transfer is mandatory for in vivo testing. Adenovirus vectors have a number of advantages for gene delivery, including high titer production and high transfection efficiency. Adenovirus can infect and direct high levels of protein expression in both proliferating and quiescent cells, an important feature for use in vivo (10)
. Recombinant adenoviral vectors containing various genes are already being used in clinical trials (11)
.
We constructed a recombinant adenovirus containing the human topo II gene (Ad-hTopoII). Infection of this adenovirus into MDA-VP cells significantly enhanced their sensitivity to VP-16. Our data also indicated that the drug-sensitizing effect of Ad-hTopoII infection was selective and that infection itself was not toxic to normal human cells. The sensitizing effect of Ad-hTopoII appears to depend upon the original reduced expression level of the gene in the resistant target cells.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Decatenation Assay.
Nuclei were isolated, and extracts were prepared by incubation in 350 mM NaCl, as described previously (3)
. Serial dilutions of nuclear extracts from MDA and MDA-VP cells were used to measure the catalytic activity of topo II in decatenation assays, as described previously (3)
. The concentration of nuclear extract that resulted in 50% decatenation of kDNA was defined as 1 unit of decatenating activity.
VP-16-induced topo II-mediated DNA Cleavage Assay.
VP-16-induced DNA double-strand cleavage activity was measured as reported previously (14)
. Briefly, SV40 form I DNA (Life Technologies, Inc., Gaithersburg, MD) was incubated with nuclear extract containing either 0.5 or 2.5 units of decatenating activity in the presence of either 10 µl of DMSO or 50 µM VP-16. The generation of form II (nicked) or form III (linearized) DNA, as visualized on ethidium bromide-stained agarose gels, is an indication of DNA-cleaving activity.
SDS-KCl Precipitation Assay.
Cells (5 x 106) were radiolabeled with [3H]thymidine (ICN Biomedicals Inc., Irvine, CA) and [14C]leucine (Amersham, Arlington Heights, IL) for 24 h at 37°C. The cells were then incubated for 90 min to 2 h with varying doses of VP-16. DNA-protein complexes were covalently linked by the addition of SDS, and then KCl was added to precipitate proteins as described previously (3)
. The extent of cleavable complex was determined by calculating the 3H-labeled DNA:14C-labeled protein ratio in the precipitated DNA-protein complexes.
Drug-induced DNA-Protein Cross-Linking Assay.
SV40 DNA was uniquely 3'-end labeled with [-32P]dATP (Amersham). Nuclear extracts containing 2.5 units of decatenating activity were incubated with 0.01 µg of end-labeled SV40 DNA and varying doses of VP-16, as described previously (14)
. Data were expressed as cpm of drug-treated samples minus cpm of untreated samples.
Construction of a Recombinant Adenoviral Vector Containing the Human topo II Gene (Ad-hTopoII).
The human topo II gene was excised from pBS-hTopII plasmid (American Type Culture Collection). To subclone this cDNA, we performed PCR using forward primer 5'-GAAGATCTTCGCCGCCACCATGGAAGTGTCACCATT-3', which contains a BglII site and Kozak sequence (15)
, and reverse primer 5'-ACAAGACATTTTTTGGGTCCCT-3'. After PCR, the products (0.3 kb) were digested with BglII/Eco01091. The second fragment of human topo II gene was obtained by Eco01091/ClaI digestion of pBS-hTopII. The adenoviral vector pAvCvSv, constructed using plasmid pXCJL-1 by addition of the human cytomegalovirus promoter and the SV40 early polyadenylation signal (16
, 17)
, was digested with BglII/ClaI. The shuttle vector pAvCvSv-hTopII was constructed by subcloning the human topo II fragment into the pAvCvSv vector using a Fast-Link DNA ligation and screening kit (Epicentre Technologies Co., Madison, WI). Every junction and fragment was sequenced to confirm correct ligation. The packaging vector pBHG10 (Microbix Biosystem Inc., Ontario, Canada; Ref. 18
) and the shuttle vector pAvCvSv-hTopII were then cotransfected into 293 cells by DOTAP liposome transfection-mediated reagent (Boehringer Mannheim Corp., Indianapolis, IN). Infectious recombinant adenovirus plaques were picked 10–14 days after transfection and then propagated and screened. The viral DNA was purified, and the presence of the human topo II gene was confirmed by PCR and restriction enzyme digestion (19)
. PCR was performed using primers 5'-GTGTGGAACTAGAAGGC-3' and 5'-GGAGGTGGAAGACTGAC-3' (for the topo II gene) and 5'-TCGTTTCTCAGCAGCTGTTG-3' and 5'-CATCTGAACTCAAAGCGTGG-3' (for the adenovirus E2B fragment). PCR products were resolved in 1% agarose gel, stained with ethidium bromide, and visualized under UV light.
Purification and Infection of Ad-hTopoII Virus.
Ad-hTopoII virus was propagated in 293 cells and twice purified by cesium chloride gradient centrifugation (10)
. The virus titers were determined by plaque assay. Ad-ß-gal was used as a control. Cells in logarithmic-growth phase were infected with Ad-hTopoII or Ad-ß-gal at various multiplicities of infection (1–1000 pfu/cell) for 48 h and then treated with VP-16 or harvested for various assays.
Northern Blot Analysis.
Total RNA was extracted by Trizol Reagent (Life Technologies, Inc., Grand Island, NY). RNA (20 µg) was electrophoresed on 1% formaldehyde/agarose gel and transferred to a Hybond-N+ membrane (Amersham). A human topo II gene probe (ZII69), a generous gift of Dr. L. Liu (Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ; Ref. 20
), and ß-actin and GAPDH probes were labeled using the Rediprime DNA labeling system (Amersham).
Western Blot Analysis.
Cells (2 x 106) were seeded 1 day before treatment and then incubated with Ad-hTopoII or Ad-ß-gal for 48 h. Cells were washed with cold PBS and lysed with buffer containing the protease inhibitors aprotinin (2 µg/ml), leupeptin (2 µg/ml), pepstatin A (1 µg/ml), and phenylmethysulfonyl fluoride (100 µg/ml). Lysates were passed 10 times through a 25-gauge needle; 50 µg of protein were then solubilized in SDS sample buffer (8)
, boiled for 5 min before loading onto a 7.5% SDS-polyacrylamide gel, and then transferred to a nitrocellulose membrane. Specific protein detection was performed with a human topo II polyclonal antibody (TopoGEN Inc., Columbus, OH) and ß-actin monoclonal antibody (Amersham) using the ECL Western blotting analysis system (Amersham) according to the manufacturer’s instructions. Densitometric analysis was performed, and values were normalized with ß-actin densities.
Cytostasis Assay.
Cells (3000–5000 per 100 µl) were seeded into 96-well cell culture plates and allowed to adhere overnight. Cells were infected with the designated concentration of adenovirus for 48 h. Various doses of VP-16 were then added in triplicate. The antiproliferative activity was determined by MTT assay 48 h later, as described previously (21)
.
Band Depletion-Immunoblotting Assay.
The band depletion-immunoblotting assay was performed as described previously (3)
. Cells (106) were infected with 100 pfu/cell of Ad-hTopoII or Ad-ß-gal for 48 h before the addition of 200 µM VP-16 and further incubation at 37°C for 1 h. Cells were then lysed and boiled for 2 min. The lysate proteins were electrophoresed in SDS-polyacrylamide gel and immunoblotted using the human topo II polyclonal antibody.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Adenovirus. adenovirus contained both the human topo II gene and the appropriate adenoviral sequences, two pairs of primers were chosen for PCR. Use of pBS-hTop II (Lane 1) and pBHG10 (Lane 2) as positive control templates resulted in 530- and 860-bp bands identifying topo II and adenoviral sequences, respectively (Ref. 22
; Fig. 1
). Both bands are present in Lane 3, with Ad-hTopoII viral DNA as the template for PCR. Water served as the negative control (Lane 4). Restriction mapping further verified this result (data not shown). To exclude the contamination of wild-type adenovirus in the generation of recombinant Ad-hTopoII virus, we used a specific E1A primer to detect wild-type adenovirus for PCR. The negative PCR result (data not shown) indicated that no wild-type adenovirus was present in the Ad-hTopoII virus preparations (23)
.
|
The most significant difference between the two cell lines was the level of topo II expression (Fig. 2)
. MDA-VP cells had a >85% reduction in steady-state mRNA expression levels compared with the MDA parent cells using densitometric analysis (Fig. 2B)
. Western blot analyses confirmed these results, also showing a >85% reduction in the topo II protein level in MDA-VP cells, compared with the MDA parent cells (Fig. 3)
. Topo II-DNA complex formation in the presence of VP-16 was quantified using an SDS-KCl assay (3)
. As shown in Fig. 4
, a direct relationship was observed between complex formation in the two cell lines and their levels of topo II enzyme. This assay demonstrated that, in the MDA-VP cells, VP-16 produced 
20% of the amount of cleavable complex detected in MDA parent cells. Considering that the value of 1 in Fig. 4
represents no effect, at 100 µM VP-16, the MDA-VP cells had a value of 2 or 1 above baseline, an 80% decrease compared with the value seen with the MDA parental cells (5 above baseline). The data in Figs. 2
and 3
indicate an 85% decrease in topo II mRNA and protein, very comparable with the 80% decrease in cleavable complex formation.
|
|
|
. Using this assay, we determined that MDA-VP cells required 0.54 µg of nuclear extract protein to decatenate 50% of the kDNA, whereas MDA parent cells required only 0.31 µg. Therefore, the topo II activity per total microgram of protein in the MDA-VP cells was 43% of that in the parent cells. This finding of decreased topo II activity per unit of nuclear protein was consistent with the mRNA and protein data.
|
protein, we used equal units of topo II decatenating activity from MDA and MDA-VP cells to quantify VP-16-induced DNA double-strand cleavage of SV40 DNA. This cleavage was detected using an agarose gel system to demonstrate the linearization of the supercoiled and single-nicked SV40 DNA (forms I and II) by topo II-containing nuclear extracts in the presence of 50 µM VP-16. Comparable amounts of DNA double-strand cleavage (form III) were seen when equal decatenating units of topo II-containing nuclear extracts from MDA and MDA-VP cells were incubated in the presence of VP-16 (data not shown). This qualitative assay demonstrated that topo II from MDA parent and MDA-VP cells cleaved DNA similarly in the presence of VP-16. To quantitate the activity of drug-induced DNA double-strand cleavage and protein cross-linking by topo II from the two cell lines, we used [-32P]dATP end-labeled SV40 DNA. In Fig. 6
, 3' end-labeled SV40 DNA was used to perform a modified SDS-KCl assay to quantitate the amount of radioactive DNA that coprecipitated with the protein in the presence of varying doses of VP-16. This assay showed that drug-induced DNA cleavage by equal decatenating activities of topo II-containing nuclear extracts from the MDA and MDA-VP cells was approximately the same. These findings suggest that there are no mutations or alterations in the MDA-VP topo II that affect its ability to interact with VP-16.
|
mRNA in MDA-VP Cells Infected with Ad-hTopoII. mRNA in etoposide-resistant human breast cancer cells could be increased, MDA-VP cells were infected with Ad-hTopoII or Ad-ß-gal at a multiplicity of infection of 100 pfu/cell for 48 h. The level of topo II expression was significantly increased in MDA-VP cells after infection with Ad-hTopoII but not Ad-ß-gal (Fig. 2A
, Lanes 3 and 4). The expression of topo II in the MDA-VP cells increased 7.4-fold, from 11.9 to 87.9%. The increased expression level was dose-dependent up to 100 pfu per cell. No further increase was seen using >100 pfu per cell (data not shown). Infection of MDA parent cells with Ad-hTopoII resulted in no significant increase in topo II mRNA (Fig. 2, C and D)
.
Production of Human topo II Protein in MDA-VP Cells Infected with Ad-hTopoII.
As shown in Fig. 3
, the Mr 170,000 human topo II protein signal (24
, 25)
for MDA-VP cells is only 13.7% of that expressed in MDA parent cells. The protein level was significantly elevated in MDA-VP cells after infection with Ad-hTopoII. Relative density analysis indicated a 5.9-fold increase (Lane 3), compared with uninfected MDA-VP cells (Lane 2). Ad-ß-gal did not significantly increase the topo II protein level in MDA-VP cells (Lane 4).
Band Depletion-Immunoblotting Assay.
To determine whether the exogenous human topo II protein produced after Ad-hTopoII infection was sensitive to VP-16, the band depletion-immunoblotting assay was performed using a specific human topo II antibody. After SDS denaturation of VP-16-treated cells, drug-sensitive human topo II protein forms a covalently linked complex with cellular DNA. Therefore, exposure of the cellular topo II to VP-16 should result in depletion of the immunologically detectable band if the protein is drug sensitive because the binding of topo II to the DNA prevents it from migrating through the SDS-PAGE system (3)
. As shown in Fig. 7
(Lanes 1–4, left to right), human topo II protein from both MDA parent and MDA-VP cells was sensitive to VP-16. The level of topo II protein was elevated 6-fold in the MDA-VP cells after infection with Ad-hTopoII (Fig. 7
, Lane 5), compared with either control cells (Lane 3) or Ad-ß-gal-infected cells (Lane 7). Depletion of this band from Ad-hTopoII-infected cells treated with VP-16 indicated that the exogenous human topo II protein produced after infection was drug sensitive.
|
.
, infection with Ad-hTopoII significantly increased the sensitivity of the MDA-VP cells in a dose-dependent manner. Treatment with 10 µM VP-16 yielded only 13% cytostasis in uninfected MDA-VP cells. This cytostatic activity was increased 4.5-fold to 58% by 100 pfu/cell Ad-hTopoII. No further increase was seen using 1000 pfu/cell. In contrast, Ad-ß-gal had no effect on cell sensitivity to VP-16. There was no significant difference in cytopathic effect after exposure to Ad-hTopoII alone, compared with Ad-ß-gal alone at viral doses below 100 pfu/cell. Thus, transfer of the human topo II gene using the Ad-hTopoII vector increased not only human topo II mRNA expression and topo II protein production but also cellular sensitivity to the cytotoxic actions of VP-16.
|
on HEL and HFC. on normal human cells, we infected HFC and HEL cells with 100 pfu/cell Ad-hTopoII or Ad-ß-gal, and cell sensitivity to 10 µM VP-16 was subsequently quantified. Both cell lines were relatively resistant to VP-16, with 9 and 17% cytostasis, respectively, after exposure to 10 µM alone (Fig. 9)
. No significant cytopathic effect was observed after infection with either Ad-hTopoII or Ad-ß-gal alone. In contrast to our finding using MDA-VP cells, neither Ad-hTopoII nor Ad-ß-gal increased the sensitivity of HEL or HFC cells to VP-16 (Fig. 9)
.
|
or Ad-ß-gal. The expression of human topo II mRNA and protein was analyzed by Northern blot and Western blot analyses. Averages from three independent experiments are shown in Fig. 10
. Expression of human topo II mRNA and protein in HEL cells infected with Ad-hTopoII was only slightly elevated. There was also a small increase in human topo II protein in the HFC after infection with Ad-hTopoII. However, Ad-ß-gal infection also resulted in slightly increased human topo II mRNA and protein production, indicating that the lack of increased sensitivity could result from failure of the vector to substantially increase topo II mRNA and protein production in the normal cells. Staining with 5-bromo-4-chloro-3-indolyl-ß-D-galactopyranoside in Ad-ß-gal-infected cells confirmed viral uptake in both HEL and HFC. Therefore, lack of enhanced topo II expression and protein production was not due to the inability of the adenoviral vector to infect these normal cells.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
gene. The adenoviral system provides a method of delivering a wild-type topo II gene to tumor cells with a mutated drug-resistant enzyme or to cells with decreased enzyme levels. Our studies provided evidence that drug resistance to topo II inhibitors can be circumvented by topo II gene transfer.
MDA-VP cells are resistant to the cytotoxic actions of VP-16 with an IC50 of 45 µM compared with 3 µM for the MDA parent cells and are also cross-resistant to doxorubicin and amsacrine (8)
. Neither MDA-VP nor MDA parent cells express mdr-1 or P95 (8)
. Drug accumulation studies using [3H]VP-16 revealed no difference in the accumulation of intracellular VP-16 (8)
, indicating that resistance is unlikely to be mediated by altered drug transport. Rather, resistance is presumed to result from the decreased expression of topo II (Fig. 3)
. VP-16-induced double-strand cleavage of SV40 DNA and band depletion-immunoblotting studies using lysates from VP-16-treated cells demonstrated that the topo II protein from MDA-VP cells is drug sensitive. Thus, it is unlikely that mutation in the protein resulting in defective VP-16 interaction is the etiology of the resistance.
We previously demonstrated that topo II gene transfer using a pMAM vector system increases VP-16-mediated cytotoxicity (8
, 9 , 26)
. The pTOP2-MAMneo vector, constructed and transfected into cells by calcium phosphate coprecipitation is not, however, suitable for in vivo investigations. High-efficiency gene transfer using a vector that can enter the tumor cells spontaneously is needed for animal studies to determine whether topo II gene transfer can alter drug resistance in vivo and, thus, be a potential strategy for clinical gene therapy. Recombinant adenoviral vectors efficiently infect cells and are one method used to accomplish gene transfer. Adenoviral vectors containing the p53 gene have been successful in altering tumor cells in patients with lung and head and neck cancer (27
, 28)
. Our goal was to design a recombinant adenoviral vector that would increase intracellular topo II protein, the molecular target of VP-16 and other topo II inhibitors (29, 30, 31, 32)
.
In this study, we successfully constructed a recombinant adenovirus containing the normal human topo II gene, verified by both PCR and restriction mapping. Because human topo II is a large gene (5.6 kb), we selected the pBHG10 packaging vector, which has a larger capacity for gene insertion. Use of packaging vectors like pJM17 with smaller capacities resulted in truncation of the topo II gene after homologous recombination (data not shown). The strategy described here was successful because infection with this adenoviral construct containing the human topo II gene led to the expression of topo II in MDA-VP cells and production of drug-sensitive topo II protein. Sensitivity to VP-16 was enhanced 4.5-fold in cells infected with this construct.
Our data indicated that adenovirus-mediated gene transfer provides a novel way to circumvent drug resistance in cells with decreased topo II. The topo II activity in primary breast tumors is considerably lower than that found in cervix, colon, and lung tumors (33)
. The absence of detectable topo II activity in 10% of 29 tumors evaluated implies a level of intrinsic resistance in some tumors. In addition, large variations in individual cellular topo II expression within each tumor have been described (33)
, helping to explain the heterogeneous response to topo II-directed therapy of some patients and the emergence of resistance after previously successful drug therapy. Increasing the cellular level of normal topo II in the tumor may offer a way to increase the sensitivity of the emerging resistant cells to the cytotoxic action of topo II-reactive agents.
A 4–5-fold change in resistance may be regarded by some as low. However, when one considers that chemotherapeutic drugs are normally used at or near maximum tolerated doses, a 4–5-fold change in the effectiveness of a fixed dose may, indeed, be clinically relevant. This increase is more than that achieved with high-dose protocols followed by bone marrow or stem cell rescue. High-dose methotrexate or ifosfamide showed increased efficacy and changes in tumor sensitivity at a 3-fold increase over the standard dose.
Our approach using topo II gene therapy also holds promise for clinical application because there appeared to be selective topo II up-regulation in tumor cells expressing low levels of topo II. The vector did not stimulate an increase in topo II mRNA or protein in the two normal cell lines tested nor was sensitivity to VP-16 altered after infection of normal cells. In the host, tumor cells grow side-by-side with normal cells. The ability to selectively sensitize tumor cells decreases the potential for normal cell toxicity, thus raising the therapeutic index. It is unclear why exposure of normal cells to Ad-hTopoII did not lead to enhanced topo II expression because the Ad-ß-gal vector was able to infect these cells and cause production of ß-gal protein. The tight control of topo II activity in normal cells may block sustained increases in protein production. Indeed, we have previously shown down-regulation of the endogenous human topo II gene in brain tumor cells with normal topo II levels after transfection with the Drosophila topo II gene (9)
. In those studies, we were able to distinguish exogenous from endogenous gene product by using the Drosophila gene. The mechanism of this down-regulation appeared to be a feedback mechanism via an effect on the endogenous topo II promoter (26)
.
In this study, we used the human topo II gene and, thus, were unable to determine whether the exogenous gene was not expressed in the normal cells or whether the endogenous gene was being down-regulated so that the total cellular topo II level (endogenous and exogenous) was maintained at the same level seen before infection. In contrast, the expression level of endogenous topo II in the MDA-VP cells was extremely low de novo. Therefore, it may be difficult to detect small additional decreases in topo II mRNA with strong exogenous gene transcription and translation.
Our data suggest that, regardless of the mechanisms, increased gene expression and cytotoxicity will be sustained only in tumor cells with decreased topo II. Indeed, transduction of MDA parent cells with Ad-hTopoII resulted in no significant increase in topo II mRNA (Fig. 2, C and D)
. Low levels of topo II protein, indeed, appear to be clinically relevant and to correlate with disease response to topo II inhibitors (34
, 35)
. The data presented support our hypothesis that topo II gene transfer may circumvent drug resistance by increasing the target for VP-16 and other topo II-reactive antineoplastic agents.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Supported in part by NIH Grants CA42992 (to E. S. K.), CA40090 (to L. A. Z.), and CA16672 Cancer Center Support Core Grant (to The University of Texas M. D. Anderson Cancer Center). 
2 To whom requests for reprints should be addressed, at The University of Texas M. D. Anderson Cancer Center, Department of Cancer Biology, 1515 Holcombe Boulevard, Box 173, Houston, TX 77030. Phone: (713) 792-8110; Fax: (713) 792-8747.
3 The abbreviations used are: topo II, topoisomerase II; HEL, human embryonic lung cell; HFC, human skin fibroblast cell; kDNA, kinetoplast DNA; pfu, plaque-forming unit(s); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Received 3/19/99. Accepted 7/21/99.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
in human renal cell carcinoma lines resistant to etoposide. J. Cancer Res. Clin. Oncol., 123: 546-554, 1997.[Medline]
gene into etoposide-resistant human breast tumor cells sensitizes the cell to etoposide. Oncol. Res., 8: 101-110, 1996.[Medline]
-adrenoceptor antagonist furobenzepine. Int. J. Oncol., 4: 789-798, 1994.
into etoposide-resistant cells: transient increase in sensitivity followed by down-regulation of the endogenous gene. Biochem. J., 319: 307-313, 1996.
in drug sensitivity revealed by inducible antisense RNA in a human leukemia cell line. Br. J. Haematol., 101: 548-551, 1998.[Medline]
dependent DNA cleavage and yeast cell killing by anthracycline analogues. Cancer Res., 58: 1886-1892, 1998. expression in small cell and non-small cell carcinoma of the lung. In search of a mechanism of chemotherapeutic response. Cancer (Phila.), 78: 729-735, 1996.[Medline]
This article has been cited by other articles:
|
|
 |
|
  L. Yan, A. Bulgar, Y. Miao, V. Mahajan, J. R. Donze, S. L. Gerson, and L. Liu Combined Treatment with Temozolomide and Methoxyamine: Blocking Apurininc/Pyrimidinic Site Repair Coupled with Targeting Topoisomerase II{alpha} Clin. Cancer Res., March 1, 2007; 13(5): 1532 - 1539. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-C. Yen and W. W. Lamph The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma Mol. Cancer Ther., May 1, 2005; 4(5): 824 - 834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Takata, T. Katagiri, M. Kanehira, T. Tsunoda, T. Shuin, T. Miki, M. Namiki, K. Kohri, Y. Matsushita, T. Fujioka, et al. Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling Clin. Cancer Res., April 1, 2005; 11(7): 2625 - 2636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wesierska-Gadek, D. Schloffer, M. Gueorguieva, M. Uhl, and A. Skladanowski Increased Susceptibility of Poly(ADP-Ribose) Polymerase-1 Knockout Cells to Antitumor Triazoloacridone C-1305 Is Associated with Permanent G2 Cell Cycle Arrest Cancer Res., July 1, 2004; 64(13): 4487 - 4497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhou, S.-F. Jia, M.-C. Hung, and E. S. Kleinerman E1A Sensitizes HER2/neu-overexpressing Ewing's Sarcoma Cells to Topoisomerase II-targeting Anticancer Drugs Cancer Res., April 1, 2001; 61(8): 3394 - 3398. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. W. Stacey, M. Hitomi, and G. Chen Influence of Cell Cycle and Oncogene Activity upon Topoisomerase IIalpha Expression and Drug Toxicity Mol. Cell. Biol., December 15, 2000; 20(24): 9127 - 9137. [Abstract] [Full Text]
|
|
|
|
 |
|
 T. A. H. Jarvinen, M. Tanner, V. Rantanen, M. Barlund, A. Borg, S. Grenman, and J. Isola Amplification and Deletion of Topoisomerase II{alpha} Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast Cancer Am. J. Pathol., March 1, 2000; 156(3): 839 - 847. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
